LabOS could not have been built two years ago. Three independent waves crossed in 2025–26, and the window to claim the category is roughly 18 months before incumbents pivot.
GPT-5, Claude Opus 4.7, and Gemini 2.5 Pro can now plan multi-step experiments, recover from unexpected lab state, and reason over typed scientific schemas — not just summarize. Agentic chains that were brittle in 2024 are production-ready in 2026. This is the engine that makes the LabOS agent mesh actually work.
SiLA2 v1.4 (instrument interop), Opentrons SDK v8, Automata Eva 3.0, Hamilton Venus REST, and PyLabRobot have made instruments programmable behind a uniform contract. CROs (Syngene, Aragen) now expose digital interfaces. The orchestration layer is finally buildable without bespoke integration per partner.
CDSCO's New Drugs and Clinical Trials Rules 2019 + DPDP Act 2023 + ICMR genomic data guidelines + DigiLocker health stack now constitute a coherent (if imperfect) regulatory rail. Apollo Hospitals' EHR digitization (Apollo 24/7) is at production scale. Hospital biobanks are consent-enabled. India is suddenly platform-buildable.
Ginkgo is decommissioning benches and pivoting to Cloud Lab. Recursion is doubling down on US phenomics. Isomorphic is protein-structure-only. No global player has a coherent India strategy — and they will not for ~18 months while they prove out their domestic businesses post-pivot. Window: now.
2024: reasoning models hallucinated protocols, lab APIs were proprietary, DPDP wasn't enforceable. 2028: Ginkgo Cloud Lab has an India POP, Recursion has acquired an Indian CRO, and Apollo's data has been licensed to the highest bidder. The category gets defined in 2026–27.